

CURRICUM VITAE

Name: José Alejandro López Ramírez
Date of Birth: 28/12/1961
Citizenship: Australian
Contact details: Griffith University, School of Environment and Sciences (ESC)
 Nathan, Building N34, Room 1.19
 Kessels Road, QLD 4111
 Phone ++61 7 3735-4407

QIMR Berghofer Institute of Medical Research (QIMRB)

300 Herston Road, Herston 4006
 Phone: ++61-7-3845 3794 Fax: ++61-7-3845 3510

Academic Qualifications

- 1979- 1984** Medical Sciences MD Universidad del Rosario, Bogotá, Colombia
 (Verified by the Australian Medical College, AMC reference number 2061809)
2009 Graduate Certificate in Higher Education. Griffith University (GU)

Honours, Fellowships and Prizes

- 2017-** Member of the Advisory Committee on Biologicals (ACB) of the Therapeutic Goods Administration (TGA)
2016- Council Member of the International Union of Immunological Societies
2013-2014 Griffith University Academic Committee
2008 High Flyers Think Tank on Preventative Health. Australian Academy of Sciences
2007 Award for the Advancement of Breast Cancer Research, National Breast Cancer Foundation
2006-2008 Board of Directors of the Australian Society for Medical Research (ASMR)
2004-2005 Queensland Councillor of the Australasian Society for Immunology (ASI)
2005-2015 Convener of the ASI International Visiting Speaker Program
2002 Greg Johnson Memorial Travelling Scholarship (Leukaemia Foundation)
2001 Honorary member of the Cuban Society of Immunology
2000 Becton-Dickinson Science Communication Prize. Australasian Society for Immunology
2000 Ferdinand Wortmann Price (Clinical immunology), Swiss Society of Allergology and Immunology
1999-1999 Roche Foundation Fellowship, Switzerland
1995-1997 National Distinguished Scientist Award of the Colombian Science Association (COLCIENCIAS)

Professional Appointments**Current**

- 2017-** Member of the Advisory Committee on Biologicals (ACB) of the Therapeutic Goods Administration (TGA)
2017- Steering committee Immunopaedia Project
2017- Founding member Publications Committee, IUIS
2016- Member Education Committee IUIS
2016- Program Director, Bachelor of Medical Sciences, GU, NSC
2015- Affiliate Scientist, QIMRB

- 2014- Professor, GU, NSC
 2008- Adjunct Associate Professor, University of Queensland (UQ)
 2004- Adjunct Associate Professor, GU, School of Medicine, (Gold Coast)

Previous

- 2010-2013.1 Associate Professor, GU, School of Biomolecular and Physical Sciences (BPS)
 2011-2015 Visiting Scientist, QIMRB
 2002-2011 Dendritic Cell and Cancer Laboratory, Head, QIMR
 2007-2011 Adjunct Professor, Griffith Medical Research College
 2006-2011 Adjunct Associate Professor, Queensland University of Technology (QUT)
 2008-2009 Senior Lecturer, GU, School of Biomolecular and Physical Sciences (BPS)
 2008 Jan-July Clinical Lead Educator (Infection, Inflammation & Defence System),
 Years 1 and 2, School of Medicine, UQ
 2003-2008 Adjunct Senior Lecturer, UQ
 2007-2008 Problem-Based-Learning and Advanced Life Support tutor, School of Medicine (Year 2), UQ
 2002-2008 Senior Research Officer, QIMR
 2002-2008 Adjunct Ass. Professor, GU. School of Biomolecular and Biomedical Sciences (Nathan)
 1999-2002 Research Fellow, Mater Medical Research Institute (MMRI), Brisbane
 1993-1999 *Premier Assistant, Institut de Biochimie, Université de Lausanne. Switzerland*
 1990-1993 Research officer, Ludwig Institute for Cancer Research, Lausanne Branch
 1987-1990 Research officer, *Max-Planck Institut für Biologie, Tübingen, Germany*
 1985-1987 Research officer, Queensland Institute of Medical Research, Brisbane

Track record of grant support

Currently held grants

- 2018-2019 AU\$15,000. Griffith University-Simon Fraser University Collaborative Travel Grants Scheme.
 “Drug discovery for drug-resistant breast cancer cells”

Previously held grants

- 2010-2016 Program Grant. National Breast Cancer Foundation. Satellite investigator in a Program administered by St Vincent’s Institute of Medical Research with Erik W. Thompson as **CI1**.
 “Targeting Breast Cancer Recurrence Through Epithelial Mesenchymal Plasticity”
 2008- AU\$ 134,000. 2008 Knights of the Round Table Philanthropy. **CI1, J.A. López, CI2, C. Schmidt**.
 “Breast Cancer Stem Cell & Immunotherapy”
 2011 AU\$ 10,000. **J.A. López** and P. Li. Griffith University and Simon Fraser University Collaborative Travel Grants Scheme 2011
 2009-2011 AU\$481,270 (worth AU\$1,042,650 total). Australian Research Council Linkage Grant. **J. A. López, C. A. Wells, A. Suhrbier, G.M. Boyle, D. J. Naylor, R. J. Brown**. “Characterisation of the Anti-Inflammatory Pathway Targeted by Chaperonin 10”
 2009-2011 AU\$50,000. Research Infrastructure Support Services (RISS). C.W. Schmidt. **J. A. López, D.A. Walker**. “Dendritic Cell Immunotherapy”
 2009-2010 AU\$ 164,000. Cancer Council Queensland, **CIA, J.A. López, CIB, BA Reynolds**. “Breast cancer stem cells as a model for therapy”

- 2009** AU\$ 25,226. Griffith University Research Grant (GURG), **J.A. López**. “Immunological Potential of Breast Cancer Stem Cells”
- 2009** AU\$ 34,692. Griffith Medical Research College, **J.A. López**. Jeff Gorman, Derek Kennedy. “What Makes Breast Cancer Stem Cells Different?”
- 2009** AU\$1,500. Griffith University Learning and Teaching Grant. **J. A López**, Diane Watters, Chris Love. “Evaluation of Audience Response Systems (“Clickers”) in the Teaching of Core (Year 2/3) Science Subjects in Smaller Groups”
- 2008** AU\$ 2,500. Griffith University ARC Linkage Projects Preparation Support, GULPPS (37917). **J.A. López**. “Characterisation of a new anti-inflammatory pathway activated by chaperonin 10”
- 2007-2008** AU\$156,000. Queensland Cancer Fund. M. Smithers CI1, C. Schmidt CI2, M. O’Rourke CI3, **J. A. Lopez** CI4, T. Wolfel CI5, N. Martinez CI6, K.E.O. Ellem CI7. “Coordination and immunological analysis of a Phase III immunotherapy trial for patients with Stage IIIB/C melanoma”
- 2007-2008** AU\$160,000. Atlantic Philanthropic Foundation. R.A. Gardiner CI1 J. Vieweg CI2, D. Nicol CI3, C. Schmidt CI4, M. Burger CI5, **J. A. Lopez** CI6. “A randomised vaccine trial of men at very high risk of metastases following radical prostatectomy”
- 2007-2008** AU\$156,000. Queensland Cancer Fund. R.A. Gardiner CI1 J. Vieweg CI2, D. Nicol CI3, C. Schmidt CI4, M. Burger CI5, **J. A. Lopez** CI6. “A randomised vaccine trial of men at very high risk of metastases following radical prostatectomy”
- 2007** AU\$50,000. QIMR (Atlantic Philanthropic Foundation) Institutional (competitive) Grant. **JA López**. “Pilot Study of Monocyte Isolation Methods for GMP Use”
- 2007** AU\$50,000. Suncorp Ride for Research. **JA López**. “The basis of the success of a DC-based immunotherapy against melanoma”
- 2005-2007** AU\$150,000. National Breast Cancer Foundation. **J.A. López** CI1, B.A Reynolds CI2, S. Lakhani CI3, C. Schmidt CI4, “Mammospheres for immunotherapy”
- 2006** AU\$250,000. Golden Casket Foundation. S. Lakhani, Principal Researcher; G. Chevenix-Trench, N. Hayward, **J.A. López**, N. Subramanian, P. Webb, A. Spurdle and J. Young. “Equipment grant: Aperio ScanScope T2 system”
- 2005-2006** AU\$143,400. Queensland Cancer Foundation. Michael McGuckin CI1, **J.A. López** CI2, Andreas Obermair CI3. “CA125 (MUC16) in the immunology of ovarian cancer”
- 2004-2007** AU\$472,500. NH&MRC Project Grant. C. Schmidt CI1, **J.A. López** CI2, K.A.O. Ellem CI3. “Immunological mechanisms of clinical responsiveness to immunotherapy for metastatic melanoma”
- 2003-2006** AU\$250,000. QIMR (Atlantic Philanthropic Foundation) Institutional (competitive) Grant. “Understanding and improving cell-based therapy of advanced metastatic melanoma with optimised patient pre-treatment, optimised therapies, and functional genomics”
- 2003-2004** AU\$140,000. Queensland Cancer Foundation. M.A. McGuckin CI1, **J.A. López** CI2) “Exploiting the discovery of the CA125 gene to improve diagnosis, define targets for immunotherapy and understand the biology of ovarian cancer”
- 2003** AU\$15,000. French Embassy in Australia. (**J.A. López**, J.A. Londoño). “Targetting telomerase alternative splicing forms for dendritic cell-based cancer immunotherapy”

CV Professor JA LOPEZ

- 2001-2003** AU\$189,414. Breast Cancer Foundation. Kathleen Cuninghame Research Grant, (**J.A. López** CI1, D.N.J. Hart CI2) “Effects of Breast Carcinoma on Dendritic Cells”
- 2002** AU\$4,200. Greg Johnson Memorial Travelling Scholarship (Leukaemia Foundation) to attend the DC2002 Meeting in Bamberg, Germany; September 19-24, 2002
- 2001** AU\$15,000 John P. Kelly Foundation. Grant 2001-17 (**J. A. López**). Purchase of cellular biology equipment: an ELISPOT reader”
- 2001** AU\$1,000. Ian Potter Foundation travel fellowship to attend the 7th ISHAGE meeting in Quebec Canada, June 14-17, 2001
- 2001** AU\$2,000 Queensland Cancer Foundation travel fellowship to attend the 1ST International Workshop on Vaccine Adjuvants, Havana Cuba, December 4-8,2001
- 1999** AU\$112,000. UQ, Infrastructure grant. (D.N.J. Hart, Principal applicant, G Hill, **J.A. López**, M. Wykes, M. McGuckin). Multidetector Scintillation and Luminescence Counter
- 1999** AU\$ 372,029. Welcome Trust. Major Equipment Grant, 062807/Z/00/Z. (D.N.J. Hart, Principal applicant; G.R. Hill, M. Kato, **J.A. López** and M. Wykes, co-applicants). Gammacell 40 Exactor Self-contained Low Dose Rate Research Irradiator
- 1999-2000** CHF 50,000. Stanley Johnson Foundation, Switzerland. (Giampietro Corradin **J.A. López** co-investigators) “A synthetic Malaria vaccine candidate”
- 1999-2000** AU\$ 15,000. John P. Kelly. Grant 99-0019. (Yuko Osugi, PI; **J.A. López** and D.N.J. Hart). “Organisation of blood DC preparation and loading for multiple myeloma”
- 2000** AU\$2,000. Ian Potter Foundation travel fellowship to attend the Keystone symposium on tumour immunotherapy, Santa Fe, New Mexico January, 2000.
- 1998-2000** CFH 85,000. OM Pharma, Switzerland. Grant OM-174-1998-16/B. (G. Corradin, **J.A. López**, F. Spertini, C. Weildenman, co-investigators). “Phase I human trial evaluating the synthetic peptide *Pf*CS 282-383, a malaria vaccine candidate”
- 1998-2000** CHF 112,000. World Health Organization, Switzerland. Preclinical. Grant 980290. (**J.A. López**, Giampietro Corradin co-investigators) “Phase I clinical trial of a synthetic malaria vaccine”
- 1998-1999** CHF 50,000. Roche Foundation. Switzerland. (**J.A. López** Fellowship recipient) “Phase I Malaria vaccine Trial”
- 1994-1995** CHF 15,000. Stanley Johnson Foundation, Switzerland. (Giampietro Corradin, **J.A. López** co-investigators) “Malaria vaccine: Identification of cytotoxic, helper and B cell epitopes in humans using sporozoite protein synthetic antigens”
- 1997-1998** CHF 80,000. Stanley Johnson Foundation, Switzerland. (**J.A. López**, Giampietro Corradin co-investigators) “A synthetic Malaria vaccine candidate”
- 1994-1998** CHF 80,000. World Health Organization, Switzerland. Preclinical. Grant 940624. (**J.A. López**, Giampietro Corradin co-investigators) “Recognition of malaria antigens by human cytotoxic T-lymphocytes”

Teaching experience

Undergraduate teaching

- 2017-** Course Convener (ESC) at GU, Nathan. 3002ESC Clinical Pathology; 3009ESC BioMed Science Laboratory
- 2012-2016** Lecturer 3009NSC BioMed Science Laboratory, 3006NSC Biomolecular Innovations
- 2012-** Lecturer in 2007ESC Human Anatomy, 2002ESC Human Physiology
- 2009-2016** Course Convener (ESC) at GU, Nathan. 3014NSC Advanced Physiology and 3012NSC Infectious Diseases
- 2009-** Course Convener (ESC) at GU, Nathan. 3007ESC Immunology
- 2008-** Associate Professor with ESC, GU. Immunology, Advanced Physiology and Human Physiology
- 2006** Guest lecturer in “Immunology [LSB438]” at QUT
- 2004-2008** Guest lecturer in “Immunology [3007BBS]” at Griffith University
- 2002** Guest lecturer in “Medical Biotechnology [LSB609]” at QUT
- 2001-2010** Guest lecturer in “Emerging Biotechnologies BIOT 7008” at UQ
- 1995-1999** Assistant Lecturer in the Biochemistry and Immunology to 2nd and 3rd year Medicine, Pharmacy, and Science students, *Université de Lausanne*, Switzerland
- 1995-1997** Lecturer in post-graduate Immunology course and 4th year Medicine students, *Universidad del Valle*, Cali, Colombia

Hosted of Sabbatical Fellows

- 2012** Prof. Paul Li, from Simon Fraser University, Vancouver, Canada. Funded by the Griffith University/Simon Fraser exchange program. “Study of the interaction of a single dendritic cell and single tumor cell for cancer drug target discovery”
- 2003** Dr. Arturo Londono-Vallejo, from the INSERM Unit 434, -*Génétique de Tumeurs Centre d'Etudes du Polymorphisme Humain*.75010 Paris. Funded by a grant from the French Embassy in Australia. “Evaluation of Telomerase Activity in Melanoma Cell Lines and Antigenicity of Telomerase Variants”

Postdoctoral Research Fellows

- 1999-2001** Dr. Yuko Osugi, Now, staff Paediatrician at Osaka University Graduate School of Medicine. Publication 58. “Comparison of the Efficiency of Human Blood DC vs MoDC”

Successful PhD Scholars

- 2014-2018** Debottam Sinha. Griffith University. Recipient of the prestigious international PhD scholarship of GU. Publications 47, 48, 81, 82. “Deciphering the role of CEP55 as a potent oncogene and a potential therapeutic target against triple negative breast cancer”. Co-supervised with Kum Kum Khanna (QIMR). QIMR Top-up scholarship. Currently post doc at QIMR.
- 2014-2018** Rocio Jimenez Martinez. Griffith University. Recipient of the prestigious international PhD scholarship of GU. Publications 45. “Exploiting biotoxins as small molecule enhancers for cancer immunotherapy”. Co-supervised with John Miles (QIMRB), and Derek Kennedy (GU). Currently post doc at QIMR.
- 2012-2016** Adnan Naim. Griffith University. Recipient of the prestigious international PhD scholarship of GU. “The Role of G3BPs in the Stress Response Pathway”. Co-supervised with Derek Kennedy (GU).

CV Professor JA LOPEZ

- 2007-2010** Brian Morrison. Griffith University. Recipient of the prestigious international PhD scholarship of GU. Publications 35, 36, 39, 40, 52, 54, 61. "Evaluation of breast cancer stem cells in an animal model". Co-supervised with Derek Kennedy (GU) and Brent Reynolds (UQ). QIMR Top-up scholarship. Currently post doc at the University of Cincinnati, Ohio, USA.
- 2002-2007** Tammy Maxwell. Queensland University of Technology. Sponsored by Dean's doctoral scholarship and the QUT Faculty based Award. Publications: 26, 27, 28, 29, 33, 49, 71, 72, 73. "Optimisation of dendritic cell generation for cancer immunotherapy". Awarded Conference and Professional development scholarship from QUT and Conference scholarship from ASI. Received the award for the best poster presentation at the BIG meeting 2006. Now a practicing physician.
- 2001-2005** Alberto Pinzón-Charry, MD. University of Queensland. Sponsored by UQ/IPRS and the Paul Mackay Bolton Foundation. Publications: 22, 26, 27, 28, 29, 33, 49, 50, 51, 56, 60, 72, 74. "Functional characterisation of blood dendritic cells in patients with breast carcinoma". Awarded the ASMR scientific presentation award in 2003 and the QIMR student Award in 2004, he was also short listed (4) Best New Investigator at the ASI meeting 2004. He received the Premier's Awards for Medical Research in 2006. He obtained competitive grants for attending international (QCF) and national meetings (ASI) during of his studies. Now Paediatrics Immunology Fellow.
- 2001-2004** Cameron Turtle, BMsc, Haematologist, UQ. Sponsored by the NH&MRC scholarship Publications: 22, 24, 68, 69, 70. "The CMRF-56 Blood Dendritic Cell Preparation as a Vehicle for Multiple Myeloma Immunotherapy". Haematologist currently at the Fred Hutchinson Cancer Research Centre, Seattle, WA, USA
- 1999- 2002** Chris Ho, BMsc, UQ, sponsored by the prestigious Raelene Boyle scholarship of the Australian College of Surgeons and the Paul Mackay Bolton Foundation. Publications: 17, 20, 27, 66, 68. "Blood Dendritic Cells in Surgery and Breast Cancer". Now, Medical officer
- 1995-1999** Anilza Bonelo, *Université de Lausanne. Universidad del Valle, Cali Colombia*. Sponsored by WHO and COLCIENCIAS. Publications: 14, 16, 18, 19, 25, 46, 59, 65. "Generation and Characterisation of Human CD8 T-cell Clones". Now, Lecturer at *Universidad del Valle*, Cali.
- 1995-1998** John Mario González, MD. *Université de Lausanne/Universidad del Valle*. Sponsored by WHO and COLCIENCIAS. Publications: 11, 12, 14, 19, 63, 64. "Field Evaluation of the Immune Response to Malaria Antigens". Now, Lecturer at *Universidad Javeriana*, Bogotá, Colombia

Other PhD students

- 2004-2008** Michael Lai. University of Queensland. Sponsored by QCF. Publications: 66. "Optimising dendritic cell (DC) immunotherapy of cancer using RNA". *Co-supervision with Chris Schmidt*

Successful Master Scholars

- 2008** Imogen Gillions, UQ. "DC Cross-presentation in a Mouse Model". Co-supervised with Andreas Suhrbier (QIMR) and Chris Schmidt (QIMR). Now staff member QGen
- 2002** Manisha Pandey. Griffith University. Masters of Biotechnology (Professional practice). "Generation of CTL Clones Specific for G3BP A candidate for DC Based Immunotherapy for Breast Cancer". Now, Post-doctoral fellow

Successful Honours Scholars

- 2016** Melinda Mitchell, Griffith University. Class IIA. "Functional Analysis of a Breast Cancer-Associated Polymorphism in MCM8". Co-supervised with Kum Kum Khanna (QIMR). Now PhD Student at Griffith University, School of Natural Sciences
- 2015** Rachael Ryan, Griffith University. First Class. "Exploring the Therapeutic Potential of Venom-Derived Molecules". Co-supervised with John Miles (QIMR). Now our PhD student.
- 2014** Kate Parsons, Griffith University. First Class. "Determining the efficacy of MAPK and JAK/STAT3 pathway inhibition in triple negative breast cancer". Co-supervised with Kum Kum Khanna (QIMR). Publication 55.
- 2014** Dillon Corvino, Griffith University. First Class. "Novel Melanoma Antigen Discovery". Co-supervised with Antonia Pitchard, Nick Hayward and Chris Schmidt (QIMR). PhD student now.

CV Professor JA LOPEZ

- 2014** Manuela Tejada, Griffith University. Class IIA. "Establishing a Mammalian Two-Hybrid as an assay for evaluation of the interaction between HIV Reverse Transcriptase and the eucaryotic translation elongation factor 1 alpha". Co-supervised with David Harrich (QIMR)
- 2013** Gabor Pali, Griffith University. First Class. "Characterisation and immunolocalisation of Schistosoma japonicum acetylcholinesterase and its potential as a vaccine target". Co-supervised with Don McManus (QIMR)
- 2011** Zara Bruce, Griffith University. Class IIA. "The Effect of MUC1 Expression on the Tumorigenicity of Breast Cancer Stem Cells". Co-supervised with Chris Schmidt (QIMR)
- 2007** Imogen Guillions, QUT. First Class. "DC Cross-presentation in a Mouse Model". Co-supervised with Trevor Fosters (QUT), Andreas Suhrbier (QIMR) and Chris Schmidt (QIMR)
- 2007** Kamilla Laut, University of Aarhus, Denmark. "IL-12 secretion by dendritic cells: Influence of genetic polymorphisms on breast cancer immunotherapy"
- 2006** Guillaume Bach. *Ecole Supérieure de Biotechnologie; Université Louis Pasteur*, Strasbourg, France. "Evaluation of IL-12 response to CD40L in DC for immunotherapy". PhD graduate in France.
- 2005** Marta Slonicka. Perugia University, Italy. "Optimisation of the Generation of Monocyte-derived Dendritic Cells". Masters graduate in Germany
- 2005** Jacqui Fleming. QUT. First Class. Publication: 30. "Presentation of Tumour Antigens by Dendritic Cells". Now Research assistant at QUT.
- 2004** Lysann Sauer. *FachHochschule Lausitz*, Germany. "Generation of CTL clones specific for Breast cancer antigens". Now, PhD graduate in Germany
- 2002** Kelly Jawerth. GU. First Class. Publication: 60. "Studies on the Immunogenicity of ras-GTPase Activating Protein SH3-Domain Binding Protein". Completed Master degree, now Science teacher
- 2002** Tammy Maxwell. QUT. First Class. "Optimising a Clinically Applicable Blood Dendritic Cell Isolation Platform for an Immunotherapy Protocol".

Graduate Assistants

- 2006-2007** Kalpana Patel. Kings College, London, B App Sc. "Optimisation of DC production for clinical trials". *Co-supervision with Chris Schmidt*
- 2004-2005** Mitchel Arico. QUT graduate sponsored by contract research from Tissue Therapies on the project: "Vitro-GroDC a Novel Method for the Generation of Monocyte-derived DC"
- 2003-2005** Sandro Prato. Swiss graduate sponsored by the Bill and Gates Foundation for the project: "Cross-Presentation of Soluble Antigens by DC". Sandro won the Award for the best Poster presentation at the BIG meeting in august 2004. Publications: 26, 28, 30. Post-doctoral fellow WEHI, now working with CSL, Melbourne.

Undergraduate Students

- 2010** Ella Trembizky. Biomed Science 3rd year student GU. "Mammospheres in radiation"
- 2008** Rebecca Johnston. Science 3rd year student GU. "Characterisation of Melanoma Stem Cells"
- 2005** Marc Ellis. Biotechnology student 3rd year BSc UQ. "Evaluation of cytokine production by IL-12 for immunotherapy"
- 2001** Laura Tavelli. Lausanne University. Training period of 6 months with the project: "Optimisation of an isolation method of blood dendritic cells"
- 2001** Evelyne Rohner. Lausanne University. Training period of 6 months with the project: "Optimisation of an isolation method of blood dendritic cells"
- 2000** Gilles Bioley. Lausanne University. Training period of 8 months with the project: "Optimisation of an isolation method of blood dendritic cells". Publications: 22, 68. Now Post-doctoral fellow.

Peer Review Involvement**Journal Edition**

- 2011** Founding Associate editor for the Open Journal Frontiers in Tumor Immunity
- 2006 (June)** Convener Special Feature on "Clinical Cancer Immunotherapy" in *Immunology & Cell Biology*

Journal reviews

- 2010-** Reviewer for *Blood*
- 2009-** Reviewer for *International Journal of Cancer*
- 2005-** Reviewer for *Cancer Immunology and Immunotherapy*
- 2005-** Reviewer for *Immunology Cell Biology*
- 2006-** Reviewer for *Tissue Antigens*
- 2006-** Reviewer for *Immunology*
- 2004-** Reviewer for *Vaccine*
- 1999-2002** Assistant reviewer of manuscripts for *Blood*
- 1999-2002** Occasional reviewer of manuscripts for *Experimental Haematology*
- 1988-1990** Reviewer of manuscripts for *Immunogenetics* (10 manuscripts a year)

Grant reviews

- 2017** Member of the NH&MRC Project Grant Review Panel (GRP)2_Invited
- 2017** Member of the Peer Review Committee of the National Breast Cancer Foundation (NBCF)
- 2016** Member of the NH&MRC Project Grant Review Panel (GRP)2_Invited
- 2015** Member of the NH&MRC Project Grant Review Panel (GRP)2_Invited
- 2014** Member of the NH&MRC Project Grant Review Panel (GRP)2c
- 2011** Member of the NH&MRC Project Grant Review Panel (GRP)2b
- 2010** Member of the NH&MRC Project Grant Review Panel (GRP)2d
- 2009-** Grant Review Committee Cancer of the Cancer Australia's Priority-driven Collaborative Cancer Research Scheme (PdCCRS)
- 2008-** Reviewer for the Health Research Council of New Zealand
- 2007** Member of the NH&MRC Project Grant Review Panel (GRP)2f
- 2007-** Medical Research Council (UK)
- 2006-** Murdoch Children's Research Institute
- 2006-** Sydney Cancer Centre
- 2006-** Netherlands Organization for Scientific Research (NOW, The Netherlands)
- 2004-2006** Requested member of the NH&MRC Project Grant Review Panel (GRP) 2a
- 2003-2010** Member of the Project Grant Review Panel of the Leukaemia Foundation
- 2001-2003** Requested member of the NH&MRC Project Grant Review Panel (GRP) 2b
- 2001- 2006** Grant and Fellowship assessor for the Wellcome Trust
- 2000-** Assessor to the NH&MRC review of Research Grants

- 1999-** Member of the National Assessors Panel for Cancer Research Grants
- 1998- 2004** Assessor for the *Fonds Nationales* Research Grants (Switzerland)
- 1996-** Assessor for Colombian Research Foundation (COLCIENCIAS) Grants
- 2001-** Honours and PhD thesis referee for UQ, QUT and Griffith University

Scientific Discipline Involvement

Organization of Meetings

- 2015-2017** Organising Committee ASI Annual Conference, Brisbane, December 2017
- 2015** Co-organizer of Brisbane Immunology Group retreat-2015. Gold Coast, August 20-21
- 2014** Co-organizer of Brisbane Immunology Group retreat-2014. Gold Coast, August 21-22
- 2013** Co-organizer of Brisbane Immunology Group retreat-2013. Gold Coast, August 22-23
- 2012** Co-organizer of Brisbane Immunology Group retreat-2012. Kingscliff, August 16-17
- 2011** Co-organizer of Brisbane Immunology Group retreat-2011. Gold Coast, August 18-19
- 2010** Co-organizer of Brisbane Immunology Group retreat-2010. Gold Coast, August 19-20
- 2009** Co-organizer of Brisbane Immunology Group retreat-2009. Gold Coast, August 20-21
- 2009** Organising Committee ASI Annual Conference, Gold Coast, December 5th – 10, 2009
- 2009** Chair of the Tumour Immunology Workshop of the ASI, Gold Coast, December 5th, 2009
- 2009** Organising Committee FIMSA Immunology training course. Tangalooma, December 3–6, 2009
- 2008** Co-organizer of Brisbane Immunology Group retreat-2008. Marcoola, August 21-22
- 2008** Convener the National Scientific Conference of the ASMR, Brisbane, November 16-21
- 2007** Co-organizer of Brisbane Immunology Group retreat-2007. Caloundra, August 23-24
- 2006** Co-organizer of Brisbane Immunology Group retreat-2006. Gold Coast, August 17-18
- 2006** Co-organizer ASI Symposium at the Australian Health and Medical Research Congress. Melbourne, Nov 26 – Dec 1
- 2005** Co-organizer of Brisbane Immunology Group retreat-2005. Gold Coast, August 18-19
- 2004** Co-organizer of Brisbane Immunology Group retreat-2004. Noosa, August 19-20
- 2003** Co-organizer of Brisbane Immunology Group retreat-2003. Caloundra, August 21-22
- 2002** Co-organizer of Brisbane Immunology Group retreat-2002. Noosa, August 29-30
- 2001** Co-organizer of Brisbane Immunology Group retreat-2001. Gold Coast, August 23-24
- 2000** Co-organizer of Brisbane Immunology Group retreat-2000. Maleny, August 24-25
- 2000** Co-organizer of “Clinical DC Cancer Therapy” International Symposia, Brisbane, May 25

Contribution to Professional Societies

- 2017-** Member of the Steering Committee of Immunopaedia
- 2017-** Member of the Education Committee of the IUIS
- 2016-** Member of the Council of the IUIS
- 2015-** Elected representative of the ASI to the International Union of Immunological Societies (IUIS)
- 2006-** Member of the Australasian Doctors Association
- 2005-2015** Convener of the ASI International Visiting Speaker Program
- 2006-2008** Board of Directors of the Australian Society for Medical Research (ASMR)

- 2004-2005** Queensland Councillor of the Australasian Society for Immunology (ASI)
- 2004-2005** Convener of the QLD Premier ASMR Awards for Medical Research
- 2001-** Member of the Australian Society for Medical Research
- 1999-** Member of the Australasian Society for Immunology

Organization of Regular Seminar Series

- 2008-** Co-Convener BPS School Seminar series, GU
- 2004-** Convener Immunology Journal Club at the QIMR
- 2003 - 2006** Queensland Institute of Medical Research Immunology Seminar Series convener
- 2000 - 2002** Mater Medical Research Institute external Seminar Series convener

Commercial Research Activities

My extended involvement with the Biotechnology industry started during my work in Switzerland with the early development of the ELISPOT system in close collaboration with Zeiss (Germany), yielding current automatic plate readers and currently available world-wide. In addition, our malaria vaccine program was the result of a close interaction with partners Dictagene SA and OM Pharma (Switzerland). Since my return to Australia, I have carried out successful contract research with Miltenyi Biotec (Germany) in the development of a DC isolation protocol and GAMBRO BTC for the use of apheresis products for DC isolation. With the support of Tissue Therapies (TT, Brisbane) we evaluated VitroGro-DC as a novel resource for the generation of monocyte derived (Mo)DC.

Industrial scope of current research

Our current research developed into two commercial avenues:

1. BRINGING DC-BASED CANCER IMMUNOTHERAPY CLOSER TO THE CLINICS

a.) VitroGro-DC. A novel reagent for the generation of MoDC. In a joint research initiative with TT we established that VitroGro[®], a patented protein mix (vitronectin plus the growth factors IGF-I, IGF-II, FGF, EGF and PDGF) reflecting the extracellular matrix favours the differentiation of MoDC. Indeed, monocytes cultured in plastic coated with VitroGro-DC yield higher number of MoDC with similar or increased functional capacity than MoDC produced with the current protocols. It appears that the coating matrix provides optimal signalling for the interaction with the cytokines (IL-4 and GM-CSF) driving the differentiation. We validated the production protocols aiming to test the product in a Phase I/II clinical trial for immunotherapy in advanced (Stage IV) melanoma. Our commercial partner has already contributed \$100,000 in the initial phase of the development (via contract research). Using VitroGro-DC, we envisage to improve on the very encouraging 12% complete clinical responses achieved in our previous clinical trials.

b.) Validation of novel method for the isolation of monocytes. Building on our previous experience with apheresis products, we have now secured (in-kind funding and equipment availability) over \$50,000 from GAMBRO BCT to evaluate a novel device for the direct isolation of monocytes. The new product called ELUTRA utilises the elutriation principle for the selection of monocytes from apheresis products. This device will facilitate the preparation DC in a closed system, a necessary requirement for the wide distribution of DC-based immunotherapies.

c.) Modifiers of the function of dendritic cells. We evaluate the potential of a small compound produced locally by CBio for its functions modifying the function of human dendritic cells. This compound is in clinical trials for rheumatoid arthritis and the mode of action is unclear.

2. BREAST CANCER IMMUNOTHERAPY

Our research on breast cancer builds on the patent PCT/AU02/01136 and will add to the existing IP, likely to establish additional product focused results that will be patented as required to make a cohesive IP portfolio surrounding breast cancer antigens.

The Market size for breast cancer therapies worldwide is US\$2000-3000 million (Pharmaprojects 2002), with the anti-estrogen breast cancer market totalling US\$350 and US\$250 million within and outside the US, respectively. Current therapies include intracellular targets, gene therapy and more recently antigen based therapies. Validated targets for breast cancer therapies are highly desirable for pharmaceutical and biotechnology companies alike.

Companies with potential interest in furthering our research include two major international companies that have programs in dendritic cells (DC) and their application to cancer are, Abbott Laboratories and ExonHit Therapeutics. Abbott Laboratories is currently investigating Her2 as a potential target for breast cancer, while we identified a close link between G3BP-2's and Her2. Hence, there would be mutual benefits in partnering to develop breast cancer immunotherapy technologies. Similarly, ExonHit Therapeutics has a focus on RNA splicing factors and their role in cancer. In addition, ACT, Bionomics and PanBio are Australian companies interested in cancer therapies which will be approached after one year of completion of this project when the novel vaccine targets are validated.

Current International Patents

2001 "A method for culturing Dendritic Cells". PCT/AU02/01610

2002 "Nucleic acid and polypeptide linked to breast cancer and uses thereof". PCT/AU02/01136

PUBLICATIONS (H Index=33, cited over 2700 times)

- JAL1.** C.M. Rzepczyk, **J.A. López**, K.L. Anderson and M.P. Alpers (1988). "Investigation of the effect of monocytes with Papua New Guinea sera on *Plasmodium falciparum* in culture", International Journal of Parasitology. 18(3): 401-6 [**IF=3.393; cited=3; ERA=B**]¹
- JAL2.** U.A. Kara, D.J. Stenzel, L.T. Ingram, G.R. Bushell, **J.A. López** and C. Kidson (1988). "Inhibitory monoclonal antibody against a (myristylated) small-molecular- weight antigen from *P. falciparum* associated with the parasitophorous vacuole membrane", Infection and Immunity. 56(4): 903-9 [**IF=4.165; cited=41; ERA=A**]
- JAL3.** **J.A. López**, H.A. Reins, R.J. Etges, L.L. Button, W.R. McMaster, P. Overath and J. Klein (1991). "Genetic control of the immune response in mice to *Leishmania mexicana* surface protease", Journal of Immunology. 146(4): 1328-34 [**IF=5.788; cited=22; ERA=A**]
- JAL4.** I.F. Luescher, **J.A. López**, B. Malissen and J.C. Cerottini (1992). "Interaction of antigenic peptides with MHC class I molecules on living cells studied by photoaffinity labeling", Journal of Immunology. 148(4): 1003-11 [**IF=5.788; cited=37; ERA=A**]
- JAL5.** **J.A. López**, I.F. Luescher and J.C. Cerottini (1992). "Direct binding of peptides to MHC class I molecules on living cells. Analysis at the single cell level", Journal of Immunology. 149(12): 3827-35 [**IF=5.788; cited=9; ERA=A**]
- JAL6.** **J.A. López**, J.H. LeBowitz, S.M. Beverley, H.G. Rammensee and P. Overath (1993). "*Leishmania mexicana* promastigotes induce cytotoxic T lymphocytes in vivo that do not recognize infected macrophages", European Journal of Immunology. 23(1): 217-223 [**IF=5.103; cited=29; ERA=A**]
- JAL7.** M.A. Roggero, B. Filippi, P. Church, S.L. Hoffman, U. Blum-Tirouvanziam, **J.A. López**, F. Esposito, H. Matile, C.D. Reymond, N. Fasel and G. Corradin (1995). "Synthesis and immunological characterization of 104-mer and 102-mer peptides corresponding to the N- and C-terminal regions of the *Plasmodium falciparum* CS protein", Molecular Immunology. 32(17-18): 1301-09 [**IF=2.897; cited=44; ERA=B**]
- JAL8.** P.R. Walker, T. Ohteki, **J.A. López**, H.R. MacDonald and J.L. Maryanski (1995). "Distinct phenotypes of antigen-selected CD8 T cells emerge at different stages of an in vivo immune response", Journal of Immunology. 155(7): 3443-52 [**IF=5.788; cited=62; ERA=A**]
- JAL9.** **J.A. López**, M.A. Roggero, O. Duombo, J.M. Gonzalez, R. Tolle, O. Koita, M. Arevalo-Herrera, S. Herrera and G. Corradin (1996). "Recognition of synthetic 104-mer and 102-mer peptides corresponding to N- and C-terminal nonrepeat regions of the *Plasmodium falciparum* circumsporozoite protein by sera from human donors", American Journal Tropical Medicine and Hygiene. 55(4): 424-9 [**IF=2.592; cited=29; ERA=C**]
- JAL10.** **J.A. López**, J.M. Gonzalez, A. Kettner, M. Arevalo-Herrera, S. Herrera, G. Corradin and M.A. Roggero (1997). "Synthetic polypeptides corresponding to the non-repeat regions from the circumsporozoite protein of *P. falciparum*: recognition by human T-cells and immunogenicity in owl monkeys", Annals of Tropical Medicine and Parasitology. 91(3): 253-65 [**IF=1.429; cited=21; ERA=C**]

¹ **IF**=Journal Impact Factor (2011) and **citations** (22.12.2012), source: ISI Journal Citations Reports Excellence in Research for Australia (**ERA**) Tier, source: Australian Research Council (2010).

- JAL11.** J.M. Gonzalez, V. Olano, J. Vergara, M. Arevalo-Herrera, G. Carrasquilla, S. Herrera and **J.A. López** (1997). "Unstable, low-level transmission of malaria on the Colombian Pacific Coast", Annals of Tropical Medicine and Parasitology. 91(4): 349-58 [IF=1.429; cited=29; ERA=C]
- JAL12.** M. Arevalo-Herrera, M.A. Roggero, J.M. Gonzalez, J. Vergara, G. Corradin, **J.A. López** and S. Herrera (1998). "Mapping and comparison of the B-cell epitopes recognized on the *Plasmodium vivax* circumsporozoite protein by immune Colombians and immunized *Aotus* monkeys", Annals of Tropical Medicine and Parasitology. 92(5): 539-51 [IF=1.429; cited=24; ERA=C]
- JAL13.** G. Eberl, J. Renggli, Y. Men, M.A. Roggero, **J.A. López** and G. Corradin (1999). "Extracellular processing and presentation of a 69-mer synthetic polypeptide to MHC class I-restricted T cells", Molecular Immunology. 36(2): 103-12 [IF=2.897; cited=26; ERA=B]
- JAL14.** J.M. Gonzalez, K. Peter, F. Esposito, I. Nebie, J.M. Tiercy, A. Bonelo, M. Arevalo-Herrera, D. Valmori, P. Romero, S. Herrera, G. Corradin and **J.A. López** (2000). "HLA-A*201 restricted CD8+ T-lymphocyte responses to malaria: identification of new *Plasmodium falciparum* epitopes by IFN-g ELISPOT", Parasite Immunology. 22(10): 501-4 [IF=2.601; cited=27; ERA=C]
- JAL15.** M.A. Roggero, V. Meraldi, **J.A. López**, G. Eberl, J.C. Romero, H. Matile, B. Betschart, G. Corradin and J. Renggli (2000). "The synthetic oxidized C-terminal fragment of the *P. berghei* CS protein elicits a high protective response", European Journal of Immunology. 30(9): 2679-85 [IF=5.103; cited=23; ERA=A]
- JAL16.** A. Bonelo, D. Valmori, F. Triponez, J.M. Tiercy, G. Mentha, J. Oberholzer, P. Champagne, J.F. Romero, F. Esposito, I. Nebie, C. Barbey, P. Romero, S. Herrera, G. Corradin and **J.A. López** (2000). "Generation and characterization of malaria specific human CD8+ lymphocyte clones: Effect of natural polymorphism on T cell recognition and on the recognition of cognate antigen endogenously presented by liver cells", European Journal of Immunology. 30(11): 3079-88 [IF=5.103; cited=28; ERA=A]
- JAL17.** C.S.K. Ho, **J.A. López**, S. Vuckovic, C.M. Pyke, R.L. Hockey and D.N.J. Hart (2001). "Surgical and physical stress increase circulating blood dendritic cell counts independently of monocyte counts", Blood. 98(1): 140-5 [IF=9.898; cited=63; ERA=A*]
- JAL18.** **J.A. López**, C. Weilenman, M.A. Roggero, R. Audran, A. Bonelo, J.M. Tiercy, F. Spertini and G. Corradin (2001). "A synthetic malaria vaccine that elicits a potent and comprehensive immune response", European Journal of Immunology. 31(7): 1989-98 [IF=5.103; cited=68; ERA=A]
- JAL19.** M. Arevalo-Herrera, A. Z. Valencia, J. Vergara, A. Bonelo, K. Fleischauer, J.M. Gonzalez, J.C. Restrepo, **J.A. López**, D. Valmori, G. Corradin and S. Herrera (2002). "Identification of HLA-A2 restricted CD8+ T-lymphocyte response to *Plasmodium vivax* circumsporozoite protein in individuals naturally exposed to malaria", Parasite Immunology. 24(3): 161-9 [IF=2.601; cited=15; ERA=C]
- JAL20.** C.S.K. Ho, D. Munster, C.M. Pyke, D.N.J. Hart and **J.A. López** (2002). "Spontaneous generation and survival of blood dendritic cells in mononuclear cell culture without exogenous cytokines" Blood. 99(8): 2897-904 [IF=9.898; cited=42; ERA=A*]
- JAL21.** **J.A. López**, G. Crosbie, C. Kelly, A. M. McGee, K. Williams, R. Schuyler, R. Rodwell, S. J. Wright, K. Taylor and D.N.J. Hart (2002). "Monitoring and isolation of blood dendritic cells from apheresis products in healthy individuals: A platform for cancer immunotherapy", Journal Immunological Methods. 267(2): 199-212 [IF=2.203; cited=15; ERA=B]

- JAL22.** J.A. López, G. Bioley, C. J. Turtle, A. Pinzón-Charry, C. S. K. Ho, S. Vuckovic, G. Crosbie, M. Gillece, D. C. Jackson, D. Munster, and D.N.J. Hart (2003). "Single step isolation of blood DC by positive immunoselection". Journal Immunological Methods. 274(1-2): 47-61 [IF=2.203; cited=31; ERA=B]
- JAL23.** V. Meraldi, R. Audran, J. F. Romero, V. Brossard, J. Bauer, J.A. López and G. Corradin (2003). "OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of *Plasmodium berghei*". Vaccine. 21(19-20): 2485-91 [IF=3.766; cited=19; ERA=A]
- JAL24.** O. Perez, G. Bracho, M. Lastre, N. Mora, J. Del Campo, D. Gil, C. Zayas, R. Acevedo, D. Gonzalez, J.A. López, C. Taboada, C. Turtle and R.L. Solis (2004). Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. Immunology and Cell Biology. 82(6):603-10 [IF=3.661; cited=26; ERA=A]
- JAL25.** S. Herrera, A. Bonelo, B.L. Perlaza, Z.A. Valencia, C. Cifuentes, S. Hurtado, G. Quintero, J.A. López, G. Corradin and M.A. Arevalo-Herrera (2004). "Use of long synthetic peptides to study the antigenicity and immunogenicity of the *Plasmodium vivax* circumsporozoite protein. International Journal of Parasitology. 34(13-14):1535-46 [IF=3.393; cited=17; ERA=B]
- JAL26.** S. Prato, T. Maxwell, A. Pinzón-Charry, C.W. Schmidt, G. Corradin and J.A. López (2005). "MHC class I-restricted exogenous presentation of a synthetic 102-mer malaria vaccine polypeptide". European Journal of Immunology. 35(3):681-9 [IF=5.103; cited=13; ERA=A]
- JAL27.** A. Pinzon-Charry, C.S. Ho, R. Laherty, T. Maxwell, D. Walker, R.A. Gardiner, L. O'Connor, C. Pyke, C.W. Schmidt, C. Furnival and J.A. López (2005). "A Population of HLA-DR+ Immature Cells Accumulate in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer". Neoplasia. 7(12): 1123-32 [IF=5.946; cited=31; ERA=A]
- JAL28.** A. Pinzon-Charry, T. Maxwell, S. Prato, C. Furnival, C.W. Schmidt and J.A. López (2005). "HLA-DR+ Immature Cells Exhibit Reduced Antigen Presenting Cell Function but Respond to CD40 Stimulation". Neoplasia. 7(12):1112-22 [IF=5.946; cited=12; ERA=A]
- JAL29.** A. Pinzon-Charry, T. Maxwell, M.A. McGuckin, C.W. Schmidt, C. Furnival and J.A. López (2006). "Spontaneous Apoptosis of Blood Dendritic Cells in Patients with Breast Cancer". Breast Cancer Research. 8(1):R5 [IF=5.245; cited=25; ERA=A]
- JAL30.** S. Prato, J. Fleming, C.W. Schmidt, G. Corradin and J.A. López (2006). "Cross-presentation of a Human Malaria CTL Epitope is Conformation Dependent". Molecular Immunology. 43(13):2031-6. [IF=2.897; cited=5; ERA=B]
- JAL31.** J. Marshall, T. Forster, D. Purdie, C. Lanagan, L. O'Connor, M. O'Rourke, M. Johnson, J. See, K.A.O. Ellem, N.R. Martinez, J.A. López and C.W. Schmidt (2006). "Immunological characteristics correlating with clinical response to immunotherapy in patients with advanced metastatic melanoma". Immunology and Cell Biology. 84(3): 295-302. [IF=3.661; cited=13; ERA=A]
- JAL32.** M.G.E. O'Rourke, M.K. Johnson, C.M. Lanagan, J.L. See, L.E. O'Connor, G.J. Slater, D. Thomas, J. A. Lopez, N.R. Martinez, K.A.O. Ellem and C. W.Schmidt (2007). "Dendritic Cell Immunotherapy for Stage IV Melanoma". Melanoma Research. 17: (5):316-22 [IF=2.187; cited=24; ERA=B]
- JAL33.** A. Pinzon-Charry, C.S. Ho, T. Maxwell, M.A. McGuckin, C.W. Schmidt, C. Furnival, C. Pyke, and J.A. López (2007). "Numerical and functional defects of blood dendritic cells in early and late stage breast

Cancer”. *British Journal of Cancer*. 97(9):1251-9 [IF=5.042; cited=17; ERA=A]

- JAL34.** S. Lee, G. Di Trapani, **J. A. López** (2011). “Using student presentations of clinical case studies to integrate knowledge, revise concepts and develop graduate attributes”. *ICERI2011 Proceedings*. 4: 5731-5739. (<http://library.iated.org/view/LEE2011USI2>)
- JAL35.** L.P. Deleyrolle, G. Ericksson, B.J. Morrison, **J.A. López**, K. Burrage, P. Burrage, A. Vescovi, R.L. Rietze and B.A. Reynolds. (2011). “Determination of Somatic and Cancer Stem Cell Self-Renewing Symmetric Division Rate Using Sphere Assays”. *PLoS One*. 6(1): e15844. [IF=3.534; ERA=A]
- JAL36.** A. Ao, B. J. Morrison, H. Wang, **J. A. López**, B. A. Reynolds and J. Lu. (2011). “Response of Estrogen Receptor-positive Breast Cancer Tumorspheres to Antiestrogen Treatments”. *PLoS One*. 6(4): e18810. [IF=3.534; cited=6; ERA=A]
- JAL37.** S. Hayes, T. Di Sipio, S. Rye, **J. A. López**, C. Saunders, C. Pyke, J. Bashford, D. Battistutta and B. Newman. (2011). “Prevalence and prognostic significance of secondary lymphedema following breast cancer”. *Lymphatic Research and Biology*. 9(3): 135-141. [cited=3; ERA=C]
- JAL38.** T. Woodberry, G. Minigo, K. A. Piera, F.H. Amante, A. Pinzon-Charry, M. F. Good, **J. A. López**, C. R. Engwerda, J. S. McCarthy and N. M. Anstey. (2012). “Low level *Plasmodium falciparum* blood-stage infection causes dendritic cell apoptosis and dysfunction in healthy volunteers”. *Journal of Infectious Diseases*. 206(3):333-40 [IF=6.410; ERA=A]
- JAL39.** B. J. Morrison, M. L. Hastie, Y. S. Grewal, Zara Bruce, C. W. Schmidt, B. A. Reynolds, J. J. Gorman and **J. A. López**. (2012). “Proteomic comparison of MCF-7 tumoursphere and monolayer Cultures”. *PLoS One*. 7(12): e52692. [IF=3.534; ERA=A]
- JAL40.** C. E. Smart, B. J. Morrison, J. M. Saunus, A. C. Vargas, P. Keith, L. Reid, L. Wockner, M. A. Amiri, D. Sarkar, P. T. Simpson, C. Clarke, C. W. Schmidt, B. A. Reynolds, S. R. Lakhani and **J. A. López**. (2013). “*In vitro* analysis of breast cancer cell line tumourspheres and primary human breast epithelia mammospheres demonstrates inter- and intrasphere heterogeneity”. *PLoS One*. 8(6): e64388. [IF=3.534; ERA=A]
- JAL41.** A. Pinzon-Charry, T. Woodberry, V. Kienzle, V. McPhun, G. Minigo, D. A. Lampah, E. Kenangalem, C. Engwerda, **J. A. López**, N. M. Anstey and M. F. Good. (2013). “Apoptosis and Dysfunction of Blood Dendritic Cells in Patients with *falciparum* and *vivax* Malaria”. *J. Exp. Med.* 210(8): 1635-1646. [IF=13.853; ERA=A⁺]
- JAL42.** **J.A. López**. C. Love and D. Watters (2014). “Clickers in Biosciences: Do they Improve Academic Performance?”. *International Journal of Innovation in Science and Mathematics Education*. 22(3): 26-41.
- JAL43.** Y. S. Poo, P. A. Rudd, J. Gardner, J. A. C. Wilson, T. Larcher, M.-A. Colle, T. T. Le, H. I. Nakaya, D. Warrilow, R. Allcock, H. Bielefeldt-Ohmann, W. A. Schroder, A. A. Khromykh, **J. A. López** and A. Suhrbier (2014). “Multiple Immune Factors Are Involved in Controlling Acute and Chronic Chikungunya Virus Infection”. *PLoS Neglected Tropical Diseases*. 8(12): e3354. [IF=4.72; ERA=A⁺]

- JAL44.** A.L. Pritchard, J.G. Burel, M.A. Neller, N.K. Hayward, **J.A. López**, M. Fatho, V. Lennerz, T.S. Wölfel and C.W. Schmidt (2015). "Exome sequencing to predict neoantigens in melanoma". Cancer Immunol Res. 3(9):992-8. [IF=3.857; ERA=A+]
- JAL45.** R. Jimenez, M. P. Ikonopoulou, **J. A. López** and J. J. Miles (2017). "Immune drug discovery from venoms". Toxicon. 141:18-24. doi: 10.1016/j.toxicon.2017.11.006. [IF=2.492; ERA=A+]
- JAL46.** S. S. Ng, F. Souza-Fonseca-Guimaraes, F. de Labastida Rivera, F. H. Amante, R. Kumar, Y. Gao, M. Shee, L. Beattie, M. Montes de Oca, C. Guillerey, C. L. Edwards, R. J. Faleiro, T. Frame, P. T. Bunn, E. Vivier, D. I. Godfrey, D. G. Pellicci, **J. A. López**, K. T. Andrews, N. D. Huntington, M. J. Smyth, J. McCarthy and C. R. Engwerda (2018). "Rapid loss of group 1 innate lymphoid cells during blood stage *Plasmodium infection*". Clinical & Translational Immunology. 7 (1) e1003. doi.org/10.1002/cti2.1003.
- JAL47.** M. Kalimutho, D. Sinha, J. Jeffery, K. Nones, S. Srihari, W. C. Fernando, P. H. Duijf, C. Vennin, P. Raninga, D. Nanayakkara, D. Mittal, J. M. Saunus, S. R. Lakhani, **J. A. López**, K. J. Spring, P. Timpson, B. Gabrielli, N. Waddell and K. K. Khanna. (2018). "CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer". EMBO Mol Med. 10(9). e8566. doi: 10.15252/emmm.201708566. [IF=9.249; ERA=A+]
- JAL48.** D. Sinha, M. Kalimutho, J. Bowles, A. L. Chan, D. J. Merriner, A. L. Bain, J. L. Simmons, R. Freire, **J. A. López**, R. M. Hobbs, M. K. O'Bryan and K. K. Khanna. (2018). "Cep55 overexpression causes male-specific sterility in mice by suppressing Foxo1 nuclear retention through sustained activation of PI3K/Akt signaling.". FASEB J. 2018 Sep;32(9):4984-4999. doi: 10.1096/fj.201701096RR. [IF=5.498; ERA=A+]

(ii) Reviews

- JAL49.** J.L. Maryanski, J.L. Casanova, K. Falk, H. Gournier, C. Jaulin, P. Kourilsky, F.A. Lemonnier, R. Luthy, H.G. Rammensee, O. Rotzschke, C. Servis and **J.A. López** (1997). "The diversity of antigen-specific TCR repertoires reflects the relative complexity of epitopes recognized". Human Immunology. 54(2): 117-28 [IF=2.837; cited=17; ERA=B]
- JAL50.** M.A. Roggero, C. Weilenmann, A. Bonelo, R. Audran, J. Renggli, F. Spertini, G. Corradin and **J.A. López** (1999). "*Plasmodium falciparum* CS C-terminal fragment: preclinical evaluation and phase-I clinical studies". Parassitologia. 41(1-3): 421-4 [cited=17]
- JAL51.** G.J. Clark, N. Angel, M. Kato, **J.A. López**, K. Macdonald, S. Vuckovic and D.N.J. Hart (2000). "The role of dendritic cells in the innate immune system". Microbes and Infection. 2(3): 257-72 [IF=3.101; cited=52; ERA=A]
- JAL52.** **J.A. López** and D.N.J. Hart (2002). "Current use of dendritic cells in cancer immunotherapy", Current Opinion in Molecular Therapeutics. 4(1): 54-63 [IF=3.676; cited=25]
- JAL53.** A. Pinzon-Charry, T. Maxwell and **J.A. López** (2005) "Dendritic Cell Dysfunction in Cancer: A Mechanism for Immunosuppression". Immunology and Cell Biology. 83(5):451-61 [IF=3.661; cited=76; ERA=A]

- JAL54.** A. Pinzon-Charry, C.W. Schmidt and **J.A. López** (2006). “Dendritic cell-based Immunotherapy for Breast cancer”. Expert Opinion on Biological Therapy. 6 (6):591-604 [IF=3.505; cited=12]
- JAL55.** **J.A. López** and A. Pinzon-Charry (2006). “Immunosuppression and Dendritic Cell Dysfunction”. Modern Aspects of Immunobiology. 18: 20-21
- JAL56.** B.J. Morrison, C.W. Schmidt, S.R. Lakhani, B.A. Reynolds and **J. A. López** (2008). “Breast Cancer Stem Cells: Implications for Therapy of Breast Cancer”. Breast Cancer Research. 10: 210. [IF=5.245; cited=22; ERA=A]
- JAL57.** M.A. Neller, **J.A. López**, C.W. Schmidt (2008). “Antigens for cancer immunotherapy”. Seminars in Immunology. 20(5):286-95 [IF=6.393; cited=21; ERA=A]
- JAL58.** F. Al-Ejeh, C.E. Smart, B.J. Morrison, G. Chenevix-Trench, **J.A. López**, S.R. Lakhani, M.B. Brown, and K.K. Khanna (2011). “Breast cancer stem cells: treatment resistance and therapeutic opportunities”. Carcinogenesis. 32(5):650-8. [IF=5.702; cited=6; ERA=A]
- JAL59.** M. Kalimutho, K. Parsons, D. Mittal, **J. A. López**, S. Srihari, K. K. Khanna (2015). “Targeted therapies for triple-negative breast cancer: Combating a stubborn disease”. Trends in Pharmacological Sciences. 36 (12): 822-46.

(iii) Peer reviewed commentaries

- JAL60.** A. Pinzon-Charry, C.W. Schmidt and **J.A. López** (2006). “The key role of CD40L in overcoming tumor-induced dendritic cell dysfunction”. Breast Cancer Research. 8 (1): 402-3 [IF=5.245; cited=8; ERA=A]

(iv) Book Chapters

- JAL61.** **J.A. López**, J.M. Gonzalez, R. Tolle, J. Renggli, G. Eberl, B. Betschart, H. Bujard, O. Doumbo, M. Arévalo, S. Herrera, G. Corradin and M.A. Roggero (1996). "Immunogenicity of syntetic peptides corresponding to the non-repeat region of the *Plasmodium falciparum* circumsporozoite protein". In Vaccines 96: Molecular Approaches to the Control of Infectious Diseases, Cold Spring Harbor Laboratories, Cold Spring Harbor. U.S.A. pp. 255-60. ISBN: 978-087969479-1
- JAL62.** D.N.J. Hart, G.J. Clark, K. MacDonald, M. Kato, S. Vuckovic, **J.A. López** and M. Wykes (2000). "7th leucocyte differentiation antigen workshop DC section summary". Mason, D. (ed) in Leucocyte Typing VII, Oxford University Press, Oxford, England. pp. 283-94. ISBN: 19-263252-3
- JAL63.** K. Peter, R. Audran, A. Bonelo, G. Corradin and **J.A. López** (2002). "Assessing Antigen-Specific CD8⁺, CTL and IFN- γ Responses in Mice". Chapter 38. Doolan, D.L (ed), in Methods in Molecular Medicine, Malaria Methods and Protocols. The Humana Press, Totowa, N.J. U.S.A. pp. 437-44. ISBN: 89603-823-8
- JAL64.** A. Pinzon-Charry and **J. A. López** (2009). “Tumor-derived Factors Responsible for DC dysfunction”. Chapter 7. Shurin MR and Salter R (ed) in Dendritic Cells in Cancer. Springer, New York. pp. 103-117. ISBN: 9780387886107.
- JAL65.** B.J. Morrison, B.A. Reynolds, C.W. Schmidt and **J.A. López** (2011). “Stem Cells and Breast Cancer”. In Shree R. Singh (ed) Stem cell, Regenerative Medicine and Cancer. Chapter 22. ISBN: 978-1-61728-787-9.

(v) Published Conference Papers and Abstracts

- JAL66.** J.A. López, I.F. Luescher and J.C. Cerottini (1993). "Direct binding of peptides to MHC class I molecules on living cells". Journal of Cellular Biochemistry. 17C(HZ130): 59 [IF=2.868]
- JAL67.** J.A. López, M.A. Roggero, J.M. Gonzalez, J. Renggli, R. Tolle, O. Doumbo, M. Arevalo-Herrera, S. Herrera and G. Corradin (1996). "Immunogenicity of synthetic peptides corresponding to the non-repeat regions of the circumsporozoite protein". Immunobiology, 196(1-3): 112 [IF=3.205; ERA=C]
- JAL68.** J.A. López, J. Renggli, J.M. Gonzalez, G. Eberl, B. Betschart, H. Matile, M. Arévalo, S. Herrera, G. Corradin and M.A. Roggero (1996) "Immunogenicity of synthetic peptides corresponding to the non-repeat region of the *Plasmodium falciparum* circumsporozoite protein", Swiss Medical Weekly. 127(39):1625 [IF=1.895]
- JAL69.** J.A. López, C. Weilenman, M.A. Roggero, R. Audran, A. Bonelo, J.M. Tiercy, F. Spertini and G. Corradin (1998). "*Plasmodium falciparum* CS C-terminal fragment: preclinical evaluation and phase-I clinical studies". Meeting report : «Novel adjuvants currently in clinical testing November 2-4, 1998, Fondation Merieux, Annecy, France: A meeting sponsored by the World Health Organization» by M.T. Aguado *et al.* Vaccine. 17(19): 2321-8 [IF=3.766]
- JAL70.** D.N.J. Hart, S. Vuckovic, C.S.K. Ho, N. Williams, D. Khalil, J.A López, C.M. Pyke, C Kelly, R Rodwell, G.R. Hill, S. Wright, and K.A. Taylor (1999). "The influence of surgical stress, stem cell mobilization and stem cell transplantation on circulating dendritic cell numbers" 41st Meeting of the American Society of Hematology, New Orleans, USA. Blood. 94(10):636a [IF=9.898; ERA=A*]
- JAL71.** Y. Osugi, S. Vuckovic, J.A. López, D.J. Munster, M.H. Gilleece and D.N.J. Hart (2000). "A Comparison of antigen specific immune responses induced by CMRF-44+ blood dendritic cells and monocyte derived dendritic cells" 42nd Meeting of the American Society of Hematology, San Francisco, USA. Blood. 96(11): 31B [IF=9.898; ERA=A*]
- JAL72.** J.A. López, G. Bioley, C.S.K. Ho, C.J. Turtle, S. Vuckovic, G.V. Crosbie, D. Munster, S. Wright, K. Taylor, R. Rodwell, and D.N.J. Hart (2001). "A human blood dendritic cell purification platform for clinical applications" 43rd Meeting of the American Society of Hematology, Orlando, USA. Blood. 98(11): 374a [IF=9.898; ERA=A*]
- JAL73.** K. Jawerth, J. French, J. A. López, C. J. Turtle, D.N.J. Hart and D. Kennedy (2002). "G3BP and Breast Cancer Immunotherapy". International symposium on "Recent Trends in Inflammation Research", Yeungnam University, Korea. 19-42.
- JAL74.** C.J. Turtle, K.J. Radford, C.P. Allan, A. Kassianos, M. Kato, S. Vuckovic, K.J. MacDonald, J. A. López, D.C. Jackson, S. Wright, K. Taylor, P. Marlton, D. Gill, D.N.J. Hart (2004). "RNA-loading of CMRF-56 positive blood dendritic cells is a promising strategy for multiple myeloma immunotherapy". Biology of Blood and Marrow Transplantation. 10 (2): 189 Suppl. 1 [IF=3.877; ERA=A]
- JAL75.** G.A. Pietersz, C.K. Tang, K. Sheng, T. Maxwell, D. Pouniotis J. Lodding, G. Minigo, M. Plebanski, I. McKenzie, J. A. López and V. Apostolopoulos (2005). "Mannan-mediated Delivery of Protein, DNA, RNA to Antigen Presenting Cells". Tissue Antigens. 66(11):512. [IF= 2.588; cited=1; ERA=A]
- JAL76.** A. Pinzon-Charry, T. Maxwell, M.A. McGuckin, C.W. Schmidt, C. Furnival and J. A. López (2005). "Spontaneous Apoptosis of Blood Dendritic Cells in Patients with Breast Cancer". Tissue Antigens. 66(11):513. [IF=2.588; ERA=A]

- JAL77.** T. Maxwell, C. Tang, T. Forster, G.A. Pietersz, V. Apostolopoulos, and **J. A. López** (2005). “Efficient Antigen Delivery into Dendritic Cell by Transfection of mRNA Conjugated with Oxidised-Mannan and Polyethylenimine”. Tissue Antigens. 66(11):490. [IF=2.588; ERA=A]
- JAL78.** A. Pinzon-Charry, C.S.K. Ho, R. Laherty, T. Maxwell, D. Walker, R.A. Gardiner, L. O’Connor, C. Pyke, C.W. Schmidt, C. Furnival and **J. A. López** (2005). “A Population of HLA-DR⁺ Immature Cells Accumulate in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer”. Tissue Antigens. [IF=2.588; ERA=A]
- JAL79.** C.W. Schmidt, N. Martinez, M. Neller, M. Lai, **J. A. López**, C. Lanagan, L. O’Connor, D. Nicholas, M. Johnson, J. See, S. Halt, G. Slater, M.G.E. O’Rourke, S. Pavey, N. Hayward, and K.A.O. Ellem (2005). “Towards a Response Model for Dendritic Cell Immunotherapy of Advanced Metastatic Melanoma”. Tissue Antigens. 66(11):533. [IF=2.588; ERA=A]
- JAL80.** P.C.H. Li, A. Khamenehfar, B. Kosia, C. Schmidt, **J. A. López** (2013). “Cell-to-cell interaction of a mouse dendritic cell and a mouse melanoma cell studied within a microfluidic chip”. 4th ANZ Nano/Microfluidics Symposium Abstracts.
- JAL81.** D. Sinha, M. Kalimutho, J.A. Lopez and K.K. Khanna (2017). “Dual inhibition of MEK1/2 and PLK1 specifically targets aggressive breast cancer cell population with CEP55 elevated expression”. Cancer Res. July 1, (77) (13 Supplement) 1144. [IF=9.329; ERA=A*]
- JAL82.** D. Sinha, M. Kalimutho, J.A. Lopez and K.K. Khanna (2017). “Synergistic inhibition of CEP55 induces mitotic catastrophe and specifically targets aggressive breast cancer”. Annals of Oncology, 28, (suppl_5), 1 September 2017. 1661P. [IF=11.855; ERA=A*]

Representation in the scientific community

Details of participation in selected International Conferences:

- 2015 October 13-16. 11th Latin American Immunology Congress. Medellín, Colombia. **ImmunoColombia 2015**.
DC immunotherapy in melanoma. What we have learnt in 15 years.
Invited symposium speaker.
- ICI 2016.
Plenary (closing ceremony) speaker.
- Cancer Immunology
Symposium chair.
- Tumor Immunology
Oral presentations chair.
[All expenses paid]
- 2014 September 26. “DC cancer Immunotherapy and the Prospects of Mammospheres”. Invited speaker from University of Florida, Gainesville. USA
- 2014 February. Presentation: “Dendritic Cells in Malaria”. Reporting on the publication in the Journal of Experimental Medicine. Invited speaker with all expenses paid at following international institutions:
- 11th - National Institute of Health. Bogotá. Colombia
 - 11th - Colciencias. Bogotá. Colombia
 - 12th – Universidad de los Andes. Bogotá. Colombia
 - 13th – Universidad Nacional de Colombia. Bogotá. Colombia
 - 14th – Universidad de Antioquia. Medellín. Colombia
 - 20th – Universidad del Quindío. Armenia. Colombia

- 21th – Universidad del Quindío (Hospital specialists). Armenia. Colombia
- 24-28 Guest of the Global Faculty Program 2014. Instituto Tecnológico de Monterrey. Guadalajara. Mexico
- 25th – “Dendritic Cells in Malaria”. Instituto Tecnológico de Monterrey. Guadalajara. Mexico
Invited speaker with all expenses paid.
- 27th - “Dendritic Cells in Cancer”. Instituto Tecnológico de Monterrey. Guadalajara. Mexico.
Invited speaker with all expenses paid.
- 2009 September 2nd. Universidad de Chile. Santiago. Células Madres Cancerígenas en Cáncer del Seno.
Invited Speaker
- 2008 December 11th. Universidad de Antioquia. Medellin. Colombia. Células Madres Cancerígenas en Inmunoterapia contra el Cáncer del Seno. *Invited Speaker*
- 2007 October 7-11th. 5th International Workshop on Antigen Processing and Presentation. Dunk Island. Impaired Antigen Presentation Capacity by Dendritic Cells in Breast Cancer. *Invited Speaker*
- 2005 March 14th. *Institut Curie*. Paris, FRANCE.
State of the Art on DC-Immunotherapy and Future Perspectives.
Invited speaker. [Accommodation paid]
- 2005 March 19th. GAMBRO BCT. Denver, Colorado, USA.
State of the Art on DC-Immunotherapy and Future Perspectives.
Invited speaker. [Accommodation paid]
- 2003 July 17th. *Hôpital Necker des Enfants Malades*, Paris.
Best use of DC for Cancer Immunotherapy. Breast Cancer as a Model.
Invited speaker. [Accommodation paid]
- 2002 October 20th. *Fondation Jean Dausset*. Paris.
DC and cancer. A novel approach for immunotherapy; the view from Down-Under.
Invited speaker. [Accommodation and partial airfares paid]
- 2002 December 9-13. 6th Latin American Immunology Congress. Havana Cuba
A human blood dendritic cell purification platform for cancer immunotherapy.
Invited main speaker and chairperson.
[Registration, Accommodation and partial airfares paid]
- 2001 December 10-12. 1st Latin American Course of immune response induction. Havana Cuba
ELISPOT evaluation of CD8 activity
Invited lecturer. [Registration, Accommodation and partial airfares paid]
- 2001 December 4-8. 1st International Workshop on Vaccine Adjuvants. Havana Cuba
A human blood dendritic cell purification platform for cancer immunotherapy.
Main speaker and chairperson. [Registration, Accommodation and partial airfares paid]
- 2001 June 14-17. Intern. Soc. of Hematotherapy and Graft Engineering Meeting, Quebec, Canada
A human blood dendritic cell purification platform for clinical applications.
- 2000 January 21-27. Cellular Immunity and Immunotherapy of Cancer, Santa Fe, USA
Monitoring circulating dendritic cell numbers. An essential requirement for cancer immunotherapy programmes
- 1999 May 26-30. Molecular basis for Lymphocyte Responses, ENII Meeting. Les Embiez, France
Phase I human trial of a synthetic malaria vaccine
- 1998 November 2-4. Novel adjuvants in clinical testing (WHO Vaccination experts) Annecy, France
Plasmodium falciparum CS C-terminal fragment: preclinical evaluation and phase-I clinical studies.
[Registration, Accommodation and transport paid]
- 1998 July 26-31. The Malaria Vaccine Gordon Conference. Oxford, UK
A synthetic malaria vaccine
- 1998 May 5-7. Meeting of the Swiss Society of Immunology. Interlaken, Switzerland
Human CTL activity on liver cells
- 1997 September 23-25. Meeting of the Swiss Society for Immunology, Geneva, Switzerland

ELISPOT as a tool of evaluation of the CTL activity in malaria

- 1997 June 22-26. Swiss Society of Tropical Disease and Hygiene, Bern, Switzerland
Human Cytotoxic T-cell activity in malaria endemic regions
- 1996 September Cold Spring Harbour Laboratories Vaccine Conference, NY, USA
Immunogenicity of syntetic peptides corresponding to the non-repeat region of the *Plasmodium falciparum* circumsporozoite protein

Details of participation in selected National Conferences:

- 2017 Nov 27th. Postgraduate Workshop. Australasian Society of Immunology Annual Meeting. Brisbane. The Academic pathway. Invited Speaker, [all expenses paid]
- 2016 May 6th. Final EMPathy Meeting (Breast Cancer Network Collaborative Program) ‘Targeting Breast Cancer Recurrence through Epithelial Mesenchymal Plasticity’. *Invited Speaker*, [all expenses paid]
- 2015 July 9th. Eight EMPathy Meeting (Breast Cancer Network Collaborative Program) ‘Targeting Breast Cancer Recurrence through Epithelial Mesenchymal Plasticity’. *Invited Speaker*, [all expenses paid]
- 2013 December 2- 5. Australasian Society for Immunology, Annual Meeting. Wellington. New Zealand. Proteomic Evaluation of Relevant Antigens Expressed in Breast Cancer Stem Cells. *Oral presentation, Tumour Immunology Workshop, Invited Speaker*
- 2013 December 2- 5. Australasian Society for Immunology, Annual Meeting. Wellington. New Zealand. Apoptosis and Dysfunction of Blood Dendritic Cells in Patients with Falciparum and Vivax Malaria. *Oral presentation, Workshop 4: Infection and Immunity, Invited Speaker*
- 2013 December 2- 5. Australasian Society for Immunology, Annual Meeting. Wellington. New Zealand. *Workshop12: Non-communicable diseases, Chair*
- 2013 December 12th. Fifth EMPathy Meeting (Breast Cancer Network Collaborative Program) ‘Targeting Breast Cancer Recurrence through Epithelial Mesenchymal Plasticity’. *Invited Speaker*, [all expenses paid]
- 2012 December 2nd- 4th. Australasian Society for Immunology, Annual Meeting. *Chair*, New Investigator Award
- 2012 May 18th. 3rd EMPathy Meeting (Breast Cancer Network Collaborative Program) ‘Targeting Breast Cancer Recurrence through Epithelial Mesenchymal Plasticity’. *Invited Speaker*, [all expenses paid]
- 2011 October 23-25. Australian Society of Stem Cell Research. Annual Meeting. Blue Mountains. “Mammospheres in the Study of Breast Cancer Stem Cells” *Invited Speaker*
- 2011 September 25-29. Combio 2011. Cairns. “A novel dendritic cell line as a tool to study Host Pathogen interactions” *Invited Speaker*
- 2009 December 6-10. Australasian Society for Immunology, Annual Meeting. Gold Coast. Breast Cancer Stem Cells for Immunotherapy. *Conference organising committee, Chair, Tumour Immunology Workshop Convener and invited Speaker*
- 2006 May 31st Jun 1st. Australian Vaccine and Immunotherapeutic Development Meeting (AVID 2006). Melbourne. Spontaneous Apoptosis of Blood Dendritic Cells in Patients with Breast Cancer. *Invited Speaker*
- 2006 Nov 26th-Dec 1st. Australian Health and Medical Research Congress
Tumour Immunology Symposium, *Chair*
Immune Regulation Communications, *Chair*
A Growing Hope for Breast Cancer: Dendritic Cells, *Invited Speaker*, [all expenses paid]
- 2005 December 4-8. 35th Annual ASI Meeting. Tumour Immunology Workshop, Melbourne
A CD40 Ligand-responsive Population of HLA-DR⁺ Immature Cells Accumulate in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer.
Oral Presentation

- 2005 November 20-23. ASMR National Scientific Conference
 “ASMR National Scientific Conference”, Couran Cove
A Population of HLA-DR⁺ Immature Cells Accumulate in the Blood Dendritic Cell Compartment of Patients with Different Types of Cancer.
Oral Presentation. [all expenses paid]
- 2005 August 26–28. Australasian Dermatopathology Society Conference, Brisbane
Malignant Melanoma and its Influence on Clinical and Immunological Responses Following Dendritic Cell Immunotherapy.
Invited Speaker
- 2004 December 12-16. Australian Society of Immunology (ASI), Adelaide
Direct correlation between immunological performance and clinical outcome in a DC-based immunotherapy for advanced melanoma.
Oral presentation, Chairperson
- 2003 December 7-11. 33th Annual Conference of the ASI. Perth
The basis for an effective dendritic cell immunotherapy of advanced stage melanoma.
Oral presentation
- 2001 October 21- 24. Joint Annual Scientific Meeting of HSANZ and ASBT, Brisbane
A human blood dendritic cell purification platform for clinical applications.
Oral presentation
- 2000 December 10-15. 30th Annual Conference of the ASI. Sydney
Isolation of human blood dendritic cells for clinical applications.
Oral presentation [Science communication Award]
- 2000 May 26-June 1. 6th International Symposium on Dendritic Cells. Port Douglas
Isolation of human blood dendritic cells for clinical applications

Details of participation in selected Local Conferences:

- 2016 February 25th. Eskitis Institute Seminar. “DC immunotherapy in melanoma. What we have learnt in 15 years”. *Invited Speaker*
- 2015 August 20-21. Brisbane Immunology Group. (BIG), Annual retreat. Gold Coast. BIG Icon. *Chairperson*
- 2014 August 21-22. Brisbane Immunology Group. (BIG), Annual retreat. Gold Coast. Jonathan Sprent Oration. *Chairperson*
- 2013 August 22-23. Brisbane Immunology Group. (BIG), Annual retreat. Gold Coast. BIG Plenary session- I. *Chairperson*
- 2013 August 13th. Eskitis Institute Seminar. “Proteomic Evaluation of Relevant Antigens Expressed in Mammospheres”. *Invited Speaker*
- 2012 August 16-17th. Brisbane Immunology Group. (BIG), Annual retreat. Kingscliff. Post Graduate Plenary Session. *Chairperson*
- 2011 August 18-19th. Brisbane Immunology Group. (BIG), Annual retreat. Gold Coast. Jonathan Sprent Oration, *Chairperson*
- 2011 May 5th. QIMR Institute Faculty Seminar. “Cancer Stem Cells on the Front Page”
- 2009 August 20, 21. Brisbane Immunology Group (BIG) Meeting. Gold Coast
Chairperson
- 2009 July 29th. Griffith BPS Seminar. Nathan. Clickers on Academic Performance in Bio-medical Sciences. Have We Got The Picture? *Invited Speaker.*
- 2009 April 29th. Griffith Medical Research College 2009 Retreat.
Breast Cancer Stem Cells as Targets for Immunotherapy. *Invited speaker.*
- 2008 August 20, 21. Brisbane Immunology Group (BIG) Meeting. Noosa

Chairperson

- 2008 April 14th. QIMR.
Dendritic cells and breast cancer stem cells: a promising combination.
Invited Speaker
- 2008 January 23rd. Griffith University
Dendritic Cells and Breast Cancer. The road ahead.
Invited Speaker
- 2007 August 23rd and 24th. Session I at Brisbane Immunology Group (BIG) Annual retreat.
Chairperson
- 2007 May 23rd. ASMR Postgraduate Conference, Wesley Hospital
What ASMR does for you
Invited speaker
- 2007 May 30th. Inaugural Symposium of the Australian Centre for Vaccine Development (ACVD). Brisbane.
Dendritic Cells and Breast Cancer. The road ahead.
Invited Speaker and Chairperson
- 2006 August 28th. Australian Red Cross Blood Service.
Dendritic Cells and Breast Cancer
Invited speaker
- 2006 May 26th. CICR, Princess Alexandra Hospital
Dendritic Cells and Breast Cancer: A growing hope
Invited speaker
- 2006 May 26th. ASMR Postgraduate Conference, Wesley Hospital
ASMR a snapshot
Invited speaker
- 2005 April 7th. Cytokine Interest Group, CICR, Princess Alexandra Hospital
Methods for the evaluation of IFN- γ production by human CD8⁺ T lymphocytes
Invited speaker
- 2004 September 1st, 2nd QIMR scientific Conference. Noosa
DC and Breast Cancer
[Short listed (3) for the best scientific presentation]
- 2004 August 19, 20. Brisbane Immunology Group (BIG) Meeting. Twin Waters
Welcome Address
- 2003 August 21-32. BIG Meeting. Caloundra
Chair
- 2002 October 28th. QIMR Immunology Seminar
DC2002, Bamberg; A meeting report
- 2002 August 29-30. BIG Meeting. Noosa
Chair Postgraduate session
- 2002 March 20th. Griffith University
DC in health and disease. The Tumour Immunology Team at the MMRI
- 2001 September 3rd. "Emerging Biotechnologies", University of Queensland
Adoptive Immunotherapy
- 2001 August 23 and 24 Brisbane Immunology Meeting Gold Coast
Novelties in the detection of CD8⁺ T-lymphocyte responses
- 2001 July 13th. MMRI Seminar Series
7th International Society Hemotherapy and Graft Engineering (ISHAGE) Meeting report
- 2001 May 31st. 3rd MMRI DC Symposium. Immunotherapy Session
Isolation of Human Blood Dendritic Cells for Clinical Applications
- 2001 May 28th. QIMR Immunology Seminar
Isolation of Human Blood Dendritic Cells for Clinical Applications

- 2000 August 24th. Brisbane Immunology Group meeting
ChairSession on Immunotherapy and Vaccination
- 2000 May 25th. Clinical Dendritic Cell Cancer Therapy Symposium, Brisbane
Evaluation of the CD8 T-lymphocyte responses by ELISPOT
- 2000 May 25th. Clinical Dendritic Cell Cancer Therapy Symposium, Brisbane
Blood DC preparations
- 1999 September 20th. QIMR Immunology Seminar
Advances on a synthetic malaria vaccine

COLLABORATIONS

Collaborator	Years	Subject	Publication Nr
Dr C. Kidson (QIMR)	1985 to 1988	Dr Kidson was director of QIMR and lab head. He provided the infrastructure for my initial research	2
Prof J. Klein (Max-Planck Institute)	1987 to 1989	Prof. Klein provided the infrastructure for my initial training in cellular immunology work	3
Prof H.-G. Rammensee (Tübingen University)	1989 to date	Prof. Rammensee was senior scientist while I was in Tübingen. We pursued close collaboration on CTL evaluation in mouse models until 1997, including extraction of natural processed peptides. Scientific exchange and interaction continue to present	6, 37
Prof S. Beverley. (Harvard University)	1989 to 1992	Prof. Beverley developed the technique transgenic parasites (<i>Leishmania</i>). We implemented a β -Gal parasite model for the evaluation of CD8 responses	6
Prof J.-C. Cerottini (LICR)	1990 to 1993	Prof. Cerottini was director of the institute and Lab Head. Together we evaluated peptide driven CTL responses in mouse and new peptide binding evaluation systems	4, 5, 53
Dr I. Luescher (LICR)	1990 to 1993	Dr Luescher was a senior research Fellow at the LICR and world expert on photolabeling of synthetic peptides. We developed together the FACS-based peptide binding evaluation system	4, 5, 53
Dr J. Mariansky (LICR)	1990 to 1997	Dr Mariansky was senior research associate while I was in Lausanne. We studied together a uniquely strong in vivo model for CTL responses in mouse published as an invited review	8, 37
Dr J.-L. Casanova (Paris)	1990 to 1997	Dr Casanova was a postdoctoral Fellow whilst I was in Lausanne, provided me with the expertise of TCR cloning utilized in the evaluation of the immune response	37
Dr P. Romero (LICR)	1990 to present	Dr Romero is a senior research associate in Lausanne. We have fostered very close interactions for the CTL evaluation systems in malaria and, lately, cancer research	14, 15, 16
Dr G. Corradin (Lausanne University)	1994 to present	Dr Corradin is senior lecturer and lab head in Lausanne. Together we developed the project for the evaluation of malaria response and the clinical human trial of a malaria vaccine. Our very close interaction is still yielding publications	7, 9, 10, 12-19, 23, 25, 26, 30, 38, 48, 50, 54, 55
Dr S. Herrera (Universidad del Valle, Colombia)	1994 to 2001	Dr Herrera is the director of the Institute of Immunology in Cali. Our close interaction allowed the generation of efficient field work stations in the endemic areas in Colombia	7, 9-12, 14, 16, 19, 25, 54, 55
Dr F. Esposito (University of Camerino, Italy)	1996 to 1999	Dr Esposito has extensive field experience in Burkina Faso. In collaboration with his team at the CNLP in Ouagadougou we established crucial field work on the malaria immune response	7, 14, 16
Dr J.-M. Tiercy (Geneva Univ. Hospital)	1996 to 2002	Dr Tiercy conducts HLA research and was instrumental in the optimisation of the HLA evaluation of donors from endemic areas and clinical trial volunteers	14, 16, 18, 54
Dr F. Spertini (Lausanne Univ. Hospital)	1996 to 2002	Dr Spertini leads the clinical immunology section in Lausanne. We worked together in the execution of the Human clinical trial of a malaria vaccine candidate	18, 37, 56
Prof D.N.J. Hart (MMRI)	1999 to 2002	Prof. Hart is director of the Institute and Lab Head. His world wide recognized knowledge in the field of DC was a fundamental input in the development of my DC expertise	17, 20-22, 39, 40, 57-61
A/Prof. M. McGuckin (MMRI)	1999 to present	A/Prof. Mike McGuckin is a leader scientist in the field of mucin research. We have obtained a QCF grant to investigate the function of CA-125 (MUC-16) as potential immunotherapy target	29, 33, 63
Dr C. Pyke (Mater Hospital)	1999 to present	Dr Pyke is responsible for the breast cancer clinic at the Mater Hospital. We collaborate on the evaluation of the DC function in breast cancer	17, 20, 27, 33, 57, 65
Prof Zee Upton (Queensland University of Technology)	2003 to 2006	Dr. Upton developed an innovative matrix for the efficient delivery of growth factors. In a collaborative project we explored the application of her device for the generation of MoDC and to establish tumour cell lines	
A/Prof D.C. Jackson (U Melbourne)	2000 to 2003	A/Prof. Jackson is the head of the Department of Microbiology an Immunology at UM. We collaborated on the use of synthetic peptides for our DC research	22, 61

Collaborator	Years	Subject	Publication Nr
Dr A. Suhrbier (QIMR)	2000 to present	Dr Suhrbier has established a reference unit to evaluate immune responses. Our collaboration is based on the establishment of a large scale ELISPOT based evaluation system. We jointly hold an ARC linkage grant	
Dr C. Schmidt (QIMR)	1999 to present	Dr Schmidt is responsible for the DC-based immunotherapy unit at the QIMR. Our groups are now integrated and work together in the evaluation of the response to DC immunotherapy in melanoma	26, 27, 28, 29, 30, 31, 32, 33, 42, 44, 45, 63, 65, 66
Dr D. Kennedy (Griffith University)	2001 to present	Dr Kennedy has identified a protein over-expressed in breast cancer tissues with great potential as Tumour Associate Antigen. We collaborate in the study of its antigenicity in human cells	56
Dr Colin Furnival (Royal Brisbane Hospital/ Wesley Medical Centre)	2003 to 2009	Dr Furnival is a breast cancer surgeon with specific interest on ductal carcinoma in situ (DCIS). Together with Dr. Kennedy, we have established a collaborative program to explore the potential of a novel tumour associated protein in breast cancer	27, 28, 29, 33, 63, 65
Dr J.A. Londoño (Institut Curie, Paris)	2002 to present	Dr Londoño is a leading scientist in the research of telomerase polymorphism. We are exploring telomerase polymorphic variants as candidates for DC-based immunotherapy	
Dr O. Pérez (Finley Institute, Havana, Cuba)	2000 to present	Dr Pérez is leading the group that produces and evaluates the serotype B Neisseria meningitidis vaccine, based on the outer membrane protein (OMP). The vaccine has been administered to more than 10 million adults in the last 10 years. We are evaluating the DC activating potential of the OMP	24
Dr Vasso Apostolopoulos (ARI, Melbourne)	2003 to 2008	Dr Apostolopoulos has extensive experience with the generation and evaluation of various immunogens. We established a collaborative program to investigate DC activation and antigen delivery systems	62, 64
Dr Frank Gardiner (University of Queensland, RB&WH)	2003 to present	Dr Gardiner is a leading urologist conducting clinical research, particularly interested in DC-based immunotherapy. Supported by various joint grants, we investigate the use of RNA loading of DC with antigens derived from prostate cancer tissue	27, 65
Dr Brent A. Reynolds (McKnight Brain Institute, University of Florida)	2005 to present	Dr. Reynolds established the technique of neurospheres for the isolation of neural stem-cells. Sponsored by the NBCF we investigate the use of this methodology for isolating breast cancer stem cells	34, 35, 44, 52
Prof. Sunil Lakhani (University of Queensland, RB&WH)	2005 to present	Prof. Lakhani is a world leader breast cancer pathologist. In the context of the NBCF funded grant "Mammospheres for immunotherapy" we envisage to develop DC-based adjuvant immunotherapy for breast cancer	44, 46
Prof. Grant Morahan (Univ of Western Australia)	2006 to present	Prof. Morahan has described the association of polymorphisms in IL-12 genes and various diseases of immunological importance such as diabetes, asthma and cerebral malaria. We collaborate in a project aimed at elucidating the effect of IL-12 polymorphisms in breast cancer	
Dr. Georgia Trench (QIMR)	2006 to present	Dr. Trench has studied widely genetic markers in breast cancer. Together with Prof. Lakhani we have proposed a QIMR Breast Cancer Research Program grant. We collaborate with Dr. Trench in the project of the evaluation of the polymorphisms of IL-12 in patients with breast cancer	
Prof. Jeffrey Gorman (QIMR)	2008 to present	Prof Gorman is the head of the Proteomics laboratory at the QIMR. We study the distinguishing properties of BCSC by comparative protein array.	
Prof. Kum Kum Khanna (QIMR)	2009 to present	Prof. Khanna's interest on the effect of irradiation on cell cycle in cancer cells is being studied now on our tumoursphere culture system. Our laboratories explore together various molecules, potential therapy targets in breast cancer.	